Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer
Patient Satisfaction and Psychological Distress Related to Emerging Technologies for Cervical Cancer Screening and Diagnosis
Primary Objectives:
- To compare levels of patient anxiety, pain, and satisfaction associated with optical spectroscopy procedures and MDC with the levels associated with colposcopically-directed biopsy in the cervical cancer diagnostic setting and with Papanicolaou smear in the screening setting. This aim will be addressed in Studies A and A' -- Procedure-Related Distress and Patient Satisfaction.
- To evaluate differences in psychological distress, satisfaction, and adherence to treatment in the two arms of a randomized trial; one group will be diagnosed with usual care procedures (Papanicolaou smear and colposcopically-directed biopsy) plus optical spectroscopy and the second will receive usual care. Aim 2 will be accomplished in Study B -- Psychological Distress, Satisfaction, and Adherence Outcomes in a Randomized Trial of Optical Spectroscopy.
- To assess the psychosocial and behavioral impact of a false positive screening result. This will be done in Study C -- Impact of False Positive Screening Test on Psychological Distress and Future Screening Intentions.
- To assess provider receptivity to optical spectroscopy. Aim 4 will be accomplished in Study D -- Survey of Health Care Providers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized Clinical Trial:
Participants in this study will be interviewed before and after they see the doctor for their first visit. They will be asked about their moods and the tests used to detect cervical cancer. They will also be asked about their symptom, how it is affecting their lives, and their satisfaction with their visit.
Participants will be called approximately 2 weeks, 6 weeks, and 3 months after their appointments to answer questions about their health and quality of life, and the test and treatment they received. In addition, the participants will complete assessments at the 6, 12, 18, and 24 month clinic visits. If participants do not return for these follow-up appointments, the research staff will attempt to contact the participants to do brief interview by phone.
Research staff will also review participant's medical records and gather information on diagnosis, treatment plans and adherence.
This is an investigational study. A total of 360 patients will take part in this multicenter study. About 180 participants at M. D. Anderson will take part in this study.
Studies A and A Prime:
Participants in this study will be interviewed before they see the doctor. They will be asked about their moods and the tests used to detect cervical cancer.
During the medical tests, participants will rate their pain and how tense they are. Someone will watch them to see whether they are upset or in pain. After they see the doctor, participants will be interviewed again about their mood and how much they liked or did not like the test.
Some participants will be interviewed about their opinion of the test at the appointment when they receive their test results. Some participants will complete the Sequelae of LEEP/biopsy and medication use questionnaire. Some participants will be called 7 to 14 days and/or three months after their appointments. Some participants may answer some of the questions on a computer as well as in an interview. They will be asked to answer questions about their moods and about getting tests to detect cervical cancer. A sample of the participants will be selected to have their results visit tape recorded and to answer a few questions about what the doctor told them.
Participants may be contacted to participate in discussion groups about tests for cervical dysplasia. Participation in the discussion groups is voluntary. Research staff will also review participant's medical records and gather information on diagnosis, treatment plans and adherence.
This is an investigational study. A total of 3980 patients will take part in this multicenter study. About 2400 participants at M. D. Anderson will take part in this study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital/British Columbia Cancer Agency
-
-
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
Houston, Texas, United States, 77030
- LBJ Hospital
-
Houston, Texas, United States, 77030
- Hermann Professional Building Clinic
-
Houston, Texas, United States, 77030
- Texas Medical Center Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Studies A, A', and pilot tests
- Eligible to participate in Project 2
- Over 18
- Referred for an abnormal pap or has no history of abnormal pap
- Consented to participate in the patient outcomes project.
Study B
- Consented to participate in Project 3
- Over 18
- Referred for an abnormal pap
- Consented to participate in the patient outcome project.
Study C
- Same as Study B.
Study D
- Members of the American Society for Colposcopy and Cervical Pathology (ASCCP).
Exclusion Criteria:
Studies A, A', and pilot tests through C:
- Pregnancy
- Unable to communicate in English, Spanish, or Chinese
Study D
- None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
A
Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
|
Questionnaire
|
|
A'
Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
|
Questionnaire
|
|
B
Patients who have consented to participate in a randomized trial of optical spectroscopy.
|
Questionnaire
|
|
C
Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
|
Questionnaire
|
|
D
Health care providers.
|
Questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Compare levels of patient anxiety, pain, and satisfaction associated with optical spectroscopy procedures and MDC with the levels associated with colposcopically-directed biopsy
Time Frame: 9 Years
|
9 Years
|
|
Evaluate differences in psychological distress, satisfaction, and adherence to treatment.
Time Frame: 9 Years
|
9 Years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assess the psychosocial and behavioral impact of a false positive screening result.
Time Frame: 9 Years
|
9 Years
|
|
Assess provider receptivity to optical spectroscopy
Time Frame: 9 Years
|
9 Years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Karen Basen-Engquist, PhD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BS98-269
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.